Peter Mark Smith

Title: Inventor Peter Mark Smith – Pioneering Innovations in Cancer Treatment

Introduction

Peter Mark Smith, an accomplished inventor based in Macclesfield, GB, has made significant contributions to the field of medicinal chemistry. With a focus on developing innovative treatments for hyperproliferative disorders, his work is particularly notable for its potential impact on cancer therapies.

Latest Patents

Smith holds a patent for "Quinazoline compounds for the treatment of hyperproliferative disorders." The patent describes a quinazoline derivative represented by a specific formula, along with claims for pharmaceutical compositions containing this derivative. It highlights its utility as a medicament and outlines processes for its preparation. The quinazoline derivatives of formula I are particularly promising in the treatment of diseases such as cancer, addressing critical medical needs.

Career Highlights

Currently employed at AstraZeneca AB, a leading global biopharmaceutical company, Smith's work has contributed to advancements in pharmacological science. His single, yet impactful patent underscores his dedication to innovative research aimed at improving patient outcomes in oncology.

Collaborations

Throughout his career, Smith has had the opportunity to collaborate with esteemed colleagues, including Benedicte Delouvrie and Craig Steven Harris. These professional partnerships have enriched his research endeavors and facilitated the development of novel therapeutic solutions.

Conclusion

Peter Mark Smith exemplifies the innovative spirit of modern inventors, leveraging his expertise to create groundbreaking solutions in the treatment of hyperproliferative disorders. With his important patent contributions and collaborative efforts at AstraZeneca AB, he continues to play a vital role in the advancement of cancer treatment strategies.